Organogenesis Holdings Inc. announced that the first patient has been enrolled in its pivotal Phase III clinical trial evaluating the safety and efficacy of ReNu®, a cryopreserved amniotic suspension allograft, for the management of symptoms associated with knee osteoarthritis. ReNu consists of amniotic fluid cells and micronized amniotic membrane and contains cellular, growth factor, and ECM components.
[Organogenesis, Inc.]
0